A Composite Decision Rule of CD8+ T-cell Density in Tumor Biopsies Predicts Efficacy in Early-stage, Immunotherapy Trials.

David Dejardin Anton Kraxner Annika Blank Natascha Rieder Volker Teichgräber Nicolas Städler Ulrich Beyer Bruno Gomes Jehad Charo

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

We propose that a composite score of CD8+ T-cell density in paired biopsies taken before and on-treatment may be a new biomarker to inform on clinical outcomes in early immunotherapy clinical trials.

Keyphrases

early stage
clinical trial
ultrasound guided
randomized controlled trial
decision making
open label
neoadjuvant chemotherapy